



About Merrimack

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel therapies, paired with diagnostics, to treat patients suffering from cancer and autoimmune diseases.

Since its founding in 2000, Merrimack has used a systems biology-driven approach to develop a pipeline of five novel, potential therapies. The company is using the same systems approach to develop a companion diagnostic for each. Merrimack's two lead candidates are MM-121, the industry's first ErbB3 antagonist to enter clinical development and MM-111, a bispecific antibody fusion protein targeting ErbB2 and ErbB3. MM-121 is currently in Phase 1 trials in the United States. Later this year, MM-121 is expected to enter a Phase 1/2 trial in combination with Tarceva[®], a tyrosine kinase inhibitor which targets the epidermal growth factor receptor (EGFR), to examine their combined safety and efficacy in patients with non small cell lung cancer (NSCLC). MM-121 is expected to enter Phase 2 monotherapy trials early in 2010. MM-111 entered a Phase 1/2 trial in June 2009 in patients overexpressing ErbB2 (HER2).

MM-121 and MM-111 are among a pipeline of candidates in research and preclinical development discovered and developed out of Merrimack's Network Biology approach – a combination of computational modeling and efficient, high-throughput analysis of cell signaling networks. Merrimack's founding principle was to apply its unique biological engineering capabilities to understanding a disease mechanism and then develop a strategy to therapeutically treat it – thus enabling rational and efficient drug design superior to the industry standard. Now, with a suite of promising molecules derived from this approach, Merrimack foresees even greater benefit from its Network Biology platform.

Merrimack believes that through its Network Biology platform, the Company will continue to deliver at least one new, novel candidate into clinical development each year. In the short term, the Company expects to file investigational new drug applications ("INDs") on three other preclinical programs by the end of 2011. Merrimack is privately held and located in Cambridge, Massachusetts. For more information on Merrimack or to learn about potential career opportunities, please visit www.MerrimackPharma.com.